Completed PHASE1 INTERVENTIONAL 3-arm NCT01340820

Study of AERAS 422 in Healthy Adults

A Phase 1, Randomized, Controlled, Double-blind, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of AERAS-422 in Healthy Adults

Sponsor: Aeras

Conditions Tuberculosis

Interventions AERAS-422 BCG Tice

Updated 7 times since 2017 Last updated: Aug 15, 2012 Started: Dec 31, 2010 Primary completion: Feb 29, 2012 Completion: May 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Tuberculosis and is currently completed. Aeras leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aeras

Data source: Aeras

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• St Louis, United States